vTv Therapeutics Inc
VTVT
View Detailed Chart
39.680USD
+1.880+4.97%
Market hours （ET）Quotes delayed by 15 min
32.55MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.97%
5 Days
+10.22%
1 Month
+3.98%
6 Months
+72.97%
Year to Date
-0.78%
1 Year
+128.70%
View Detailed Chart
TradingKey Stock Score of vTv Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
vTv Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 111 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 55.20.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
vTv Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
vTv Therapeutics Inc Highlights
StrengthsRisks
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -12.03, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.18M shares, increasing 17.73% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 83.40K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
55.200
Target Price
+46.03%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
vTv Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
vTv Therapeutics Inc Info
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.
Ticker SymbolVTVT
CompanyvTv Therapeutics Inc
CEOSekhri (Paul Jai)
Websitehttps://vtvtherapeutics.com/
Related Instruments
+0.92%
-0.80%
+0.65%
+2.95%
-0.82%
+1.39%
+0.10%
-0.81%
+0.57%
+1.10%
+2.13%
-0.17%
+0.91%
+0.57%
+1.54%
0.00%
+0.13%
-0.32%
+1.22%
+1.73%Popular Symbols
246.720
-2.080 (-0.84%)
168.020
+0.500 (+0.30%)
67433.150
+849.100 (+1.27%)
260.031
-13.319 (-4.87%)
2063.230
+63.230 (+3.16%)
365.025
+3.195 (+0.88%)
4533.060
+40.540 (+0.90%)
101.832
+1.223 (+1.22%)
1.145
-0.005 (-0.47%)
159.587
-0.665 (-0.41%)
